Intravitreal injection of anti vascular endothelial growth factor agent, Lucentis (ranibizumab), for the treatment of retinopathy of prematurity
Not Applicable
- Conditions
- retinopathy of prematurity
- Registration Number
- JPRN-UMIN000013975
- Lead Sponsor
- agoya University hospital ophtalmoligy
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 30
Inclusion Criteria
Not provided
Exclusion Criteria
inflammation around the eye
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method prevention of retinal detachment serous VEGF concentration
- Secondary Outcome Measures
Name Time Method visual acuity
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms of ranibizumab are effective for retinopathy of prematurity in infants?
How does intravitreal ranibizumab compare to laser therapy in treating stage 3+ retinopathy of prematurity?
Which biomarkers correlate with ranibizumab response in retinopathy of prematurity patients?
What are the long-term adverse events of anti-VEGF therapy in preterm infants with ROP?
Are there combination therapies involving ranibizumab for aggressive posterior retinopathy of prematurity?